Following the conference call, a recording of the webcast will be available on Nasus Pharma’s investor relations website at https://ir.nasuspharma.com/investors/events/.
Neffy nasal spray shows comparable efficacy to IM epinephrine for type I allergic reactions, with 92.3% symptom resolution after 1 dose.
SAN DIEGO, Oct. 03, 2023 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients ...
Credit: ARS Pharma. Neffy is supplied as a single-dose (2mg of epinephrine) nasal spray that is administered into 1 nostril. With regard to cardiovascular effects, increases in blood pressure and ...
Epinephrine improves ROSC in cardiac arrest but does not increase favorable neurologic recovery, raising ethical and ...
Repeat doses of neffy under nasal allergen challenge demonstrate a pharmacokinetic profile greater than or similar to injection, and a pharmacodynamic profile greater than injection Company believes ...
The Food and Drug Administration approved the first needle-free alternative to the EpiPen on Friday, a single-use epinephrine nasal spray for the emergency treatment of allergic reactions, including ...
Among children with in-hospital cardiac arrest with an initial nonshockable heart rhythm who received epinephrine (adrenaline), delay in administration of epinephrine was associated with a decreased ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Fear of needles may delay treatment with injectable ...
A committee of the Food and Drug Administration's outside advisers voted Thursday in favor of an epinephrine nasal spray product, clearing a key hurdle for what could soon be the first needle-free ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results